Work

P17.02 RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2021.08.348

Authors: S. Lu, X. Yu, J. Wang, J. Zhao, Y. Yu, C. Hu, G. Feng, K. Ying, W. Zhuang, J. Zhou, J. Wu, S.J. Leaw, F. Bai, X. Lin

Institutions: Shanghai Jiao Tong University, Shanghai Chest Hospital, Zhejiang Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, State Key Laboratory of Molecular Oncology, Peking University Cancer Hospital, Third Affiliated Hospital of Harbin Medical University, Central South University, The People's Hospital of Guangxi Zhuang Autonomous Region, Sir Run Run Shaw Hospital, Zhejiang University, Fujian Provincial Cancer Hospital, First Affiliated Hospital Zhejiang University, First Affiliated Hospital of Xiamen University, BeiGene (China)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3205035240

Cites:

Cited by:

Related to: 10